Frontline pembrolizumab monotherapy for metastatic non-small cell lung cancer with PD-L1 expression ≥50%: real-world outcomes in a US community oncology setting

Frontline pembrolizumab monotherapy for metastatic non-small cell lung cancer with PD-L1 expression ≥50%: real-world outcomes in a US community oncology setting

BackgroundThis study investigated real-world time on treatment (rwToT) and overall survival (OS) for patients with metastatic non-small cell lung cancer (mNSCLC) who initiated first-line (1L) pembrolizumab monotherapy. We also explored discontinuation reasons and subsequent treatments, stratified by...

Full description

Bibliographic Details
Main Authors: Shirish M. Gadgeel, Pragya Rai, Srinivas Annavarapu, Sartaj Alam, Jerome H. Goldschmidt, Howard (Jack) West, Melissa Santorelli, Renata Eiras Martins
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-03-01
Series:Frontiers in Oncology
Subjects:
non-small cell lung cancer
pembrolizumab monotherapy
overall survival
real-world time on treatment
reasons for discontinuation
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1298603/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1298603/full

Similar Items